Latest News and Press Releases
Want to stay updated on the latest news?
-
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces...
-
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced...
-
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today...
-
If approved, the T-Cell Select reagent kit would enable automated sample preparation and the T-SPOT®.TB test to be used with blood samples stored for up to 54 hours at room temperature OXFORD, United...
-
Third quarter revenue of $19.4 million, above guidance of range of $18 - $19 million Asia-Pacific region returns to growth and sets a new quarterly sales record for the regionEurope & rest of...
-
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today...
-
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced...
-
OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today...
-
OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today...
-
Second quarter revenue of $5.8 million, a decrease of 70% compared to prior year period, due to the impact of COVID-19 Ended the quarter with approximately $165 million of cash and cash equivalents...